A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye

Inclusion Criteria:

Be at least 18 years of age Provided written informed consent Have a reported history of
dry eye Have a history of use or desire to use eye drops for dry eye

Exclusion Criteria:

Be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal), or active
ocular inflammation (e.g. follicular conjunctivitis) at Visit 1, or have been diagnosed
with ocular rosacea, or any viral or bacterial disease of the cornea or conjunctiva,
within the last 12 months Have any planned ocular and/or lid surgeries over the study
period Have corrected visual acuity greater than or equal to +0.7 as assessed by Early
Treatment of Diabetic Retinopathy Study (ETDRS) scale in both eyes at Visit 1 Have an
uncontrolled systemic disease Be a woman who is pregnant, nursing or planning a pregnancy
Be a woman of childbearing potential who is not using an acceptable means of birth
control; acceptable methods of contraception include: hormonal - oral, implantable,
injectable, or transdermal contraceptives; mechanical - spermicide in conjunction with a
barrier such as a diaphragm or condom; IUD; or surgical sterilization of partner. For
non-sexually active females, abstinence may be regarded as an adequate method of birth
control; however, if the subject becomes sexually active during the study, she must agree
to use adequate birth control as defined above for the remainder of the study Have a known
allergy and/or sensitivity to the test article or its components Have a condition or be in
a situation which the investigator feels may put the subject at significant risk, may
confound the study results, or may interfere significantly with the subject's
participation in the study Be currently enrolled in an investigational drug or device
study or have used an investigational drug or device within 45 days of Visit 1 Be unable
or unwilling to follow instructions, including participation in all study assessments and
visits